
Tazemetostat (TAZVERIK®) is included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcomas with a category 2A recommendation as the only preferred regimen for appropriate patients with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection*

Explore the efficacy data of TAZVERIK
See the efficacy data of TAZVERIK in metastatic or locally advanced epithelioid sarcoma patients.

View the safety data of TAZVERIK
Learn more about how safety and tolerability were evaluated in the clinical trial.

Questions about TAZVERIK?
Ipsen is here to help. Request to have a representative contact you.

Explore the efficacy data of TAZVERIK
See the efficacy data of TAZVERIK in metastatic or locally advanced epithelioid sarcoma patients.

View the safety data of TAZVERIK
Learn more about how safety and tolerability were evaluated in the clinical trial.

Questions about TAZVERIK?
Ipsen is here to help. Request to have a representative contact you.
*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2023.© National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed May 1, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Learn more about epithelioid sarcoma.